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ill-planned surgical procedure had been previously attempted.
They did not explain how they made their decision.
In the last century, surgeons treated the congenital vascular
malformation (CVM) solely through a surgical approach. This
“cavalier approach,” with limited knowledge of the natural history
of these lesions, often resulted in extremely poor outcomes with
high morbidity and high rates of recurrence. Dismal outcomes
were due to the natural biologic behavior of the CVM lesion.
Surgeons later learned that the embryological characteristics of the
CVMs play a critical role in its behavior.
All CVM lesions derived from an “earlier” stage of embryo-
genesis maintain their mesenchymal cell characteristics, such that
they proliferate when stimulated by incomplete excision or simple
ligation of a feeding artery. These embryonic tissue remnants,
classified as “extratruncular” lesions, are often surgically inaccessi-
ble and difficult to remove completely. Therefore, only a carefully
planned multidisciplinary approach, combining both endovascular
therapy and open surgical treatment, is able to deliver a successful
outcome, as the authors demonstrated beautifully.
Second, the authors have made a critical decision to limit the
extent of the coil embolization therapy and stent grafting, and
utilized the endovascular therapy as a means to reduce the risk of
massive bleeding during the subsequent surgery. They did not rely
solely on an endovascular approach as an independent and perma-
nent treatment. Again, they did not explain their rational of this
approach.
Up until a few decades ago, simple ligation/ablation of a
feeding artery of an AVM lesion was often performed without
knowledge of the characteristics of extratruncular AVM lesions.
This maneuver deprives the AVM lesion of its arterial supply only
temporarily, which then ultimately stimulates this embryonic tissue
remnant with mesenchymal cell characteristics. The nidus of the
lesion will soon proliferate and develop new arterial collaterals via
“neovascular recruitment,” making the condition worse. There-
fore, ligation/ablation of the feeding artery as a sole, permanent
treatment should no longer be practiced as the authors wisely
demonstrated.
Third, the authors made another critical decision to perform
ethanol sclerotherapy3 prior to surgical excision. This was a wise
decision. As before, they did not explain clearly their rationale and
why they took this approach.
The only way to achieve a curative resection of an extratruncular
AVM lesion is to completely destroy the endothelial cells of the nidus
in order to prevent its recurrence. Ethanol is the only sclerotherapy
agent that has been shown to deliver permanent destruction of the
lesion nidus (with mesenchymal cell characteristics). Because this
extratruncular lesion is not a well localized one, but rather a diffusely
infiltrating lesion, preoperative embolization therapy with N-butyl
cyanoacrylate would not have been as good a choice as ethanol
sclerotherapy to deliver effective local control. Ethanol sclerotherapy
provided extra reassurance of permanent destruction of any potential
residual cells present following excision.
The authors have successfully utilized a multidisciplinary ap-
proach to the treatment of a high risk AVM lesion,4 combining
both endovascular therapies with open surgical resection, resulting
in an excellent outcome. We continue to support and promote this
multidisciplinary approach to the AVM.
Byung-Boong Lee, MD, PhD
James Laredo, MD, PhD
Georgetown University School of Medicine
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Washington, DC
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Reply
I appreciate your comments about my article1 entitled “Mul-
tidisciplinary approach in the management of a giant arteriovenous
malformation.”
The only reason I did not explain in detail why I chose the
multidisciplinary approach to treat this AVM (endovascular thera-
pies plus open surgical resection) was that I had to write the case
using only 350 words (as a Vascular Image). I agree with all your
comments, and I also think that the multidisciplinary approach is
the best strategy to treat these lesions.
Célio Teixeira Mendonça, MD, PhD
Positivo University
Curitiba, Brazil
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Regarding “Pharmacologic risk factor management in
peripheral arterial disease: A vade mecum for vascular
surgeons”
The excellent article by Rehring et al1 suggests specific recom-
mendations for tobacco cessation, blood pressure control, lipid-
lowering agents, and antiplatelet therapy in patients with periph-
eral arterial disease (PAD). A risk factor that perhaps deserves more
extensive discussion is the presence of diabetes mellitus (DM) in
these patients.
The authors mention that, “there are little data to support that
aggressive control of blood glucose levels improves risk of MI,
stroke, vascular death, or amputation.”1 The results of an earlier
study comparing the severity and outcome of PAD inDM (n 58)
and non-DM (n  68) patients may be of interest.2 This study
showed that during a follow-up period of 4.47  1.25 years for
DM vs 4.52  1.23 years for non-DM patients (P  .85), DM
patients were five times more likely than non-DM patients to
undergo an amputation (41.4% vs 11.5%), with an odds ratio (OR)
of 5.4 (95% confidence interval [CI], 2.3-12.9; P  .0001) and
three times more likely to die (51.7% vs 25.6%), with an OR of 3.1
(95% CI, 1.5-6.4; P  .002).2
As reported in a Consensus Statement of the American Dia-
betes Association, “the natural history of PAD in diabetic patients
has not specifically been studied longitudinally, but it is known
from prospective clinical trials of risk interventions that the cardio-
vascular event rates in patients with PAD and diabetes are higher
than those of their nondiabetic counterparts.”3 This can also be
extrapolated from the fact that “PAD is marker of systemic vascular
disease involving coronary, cerebral and renal vessels, leading to an
elevated risk of events, such as myocardial infarction, stroke, and
death.”3
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A recent meta-analysis compared the effect of intensive glyce-
mic control vs conventional treatment in type 1 and type 2 DM on
the incidence of macrovascular (cardiac, cerebrovascular, or pe-
ripheral vascular) events.4 This meta-analysis showed that the
combined incidence rate ratios for any macrovascular event with
intensive glycemic control compared with conventional treatment
were 0.38 (95% CI, 0.26-0.56) in type 1 DM and 0.81 (95% CI,
0.73-0.91) in type 2 DM, indicating a substantial risk reduction in
type 1 DM and a smaller risk reduction in type 2 DM.4 These
incidence rate ratios demonstrated that the numbers of patients
who need to receive intensified treatment for 10 years to prevent
onemacrovascular event are 16 for type 1DM, 14 for low-risk type
2 DM, and seven for high-risk type 2 DM.4
Although data from randomized controlled studies are indeed
lacking, the above data2-4 suggest that aggressive control of blood
glucose levels in patients with PAD may improve the risk of
amputation, myocardial infarction, stroke, or vascular death.
Kosmas I. Paraskevas, MD, FASA
Department of Vascular Surgery
“Red Cross” Hospital
Athens, Greece
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We would like to thank Dr Paraskevas for his interest in our
article.1 Overall, we agree with his belief that diabetes is an impor-
tant risk factor for peripheral arterial disease (PAD) but chose to
limit the attention paid to it for several reasons. Conceptually, the
vade mecumwas designed to be a specific guide to the treatment of
risk factors for vascular disease and less so for their indications—
more of a “how-to” than a “why” article. As shown by the PAD
Awareness, Risk, and Treatment: New Resources for Survival
(PARTNERS) trial,2 of all risk factors for PAD, primary care
physicians are relatively successful at identifying diabetes and treat-
ing to well-known goals. In contrast to hypertension or hyperlip-
idemia, the additional diagnosis of PAD does not impact on target
goals or choice of pharmacologic agent used in treating it.
Furthermore, although patients with type 2 diabetes, both
with and without PAD, have an increased proclivity for limb loss
and death, no large prospective clinical trial has demonstrated that
intensive blood sugar management has any beneficial effect on
macrovascular outcomes. The United Kingdom Prospective Dia-
betes Study (UKPDS) randomized nearly 4000 newly diagnosed
type 2 diabetic patients to intensive pharmacologic treatment vs
dietary control.3 During 10 years of follow-up, no effect on mac-
rovascular outcomes was observed.
More recently, a large prospective clinical trial arm was halted
for an increased death rate in patients with aggressive blood glu-
cose management. The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study was designed to look at the cardiovas-
cular event rates in 10,251 adults with known type 2 diabetes
prospectively randomized to standard treatment to a hemoglobin
A1c goal of 7% to 7.9% vs intensive management with a goal of
6%.4 In response to recommendations from the Data and Safety
Monitoring Board, the study was halted after the finding that
257 patients in the intensive treatment group had died com-
pared with 203 in the standard treatment group after nearly 4
years of follow-up.5
In view of its broad recognition, lack of effect of PAD on
treatment methods or goals, and some controversy regarding the
effect of aggressive glucose management on macrovascular out-
comes, we elected to give diabetes somewhat less attention but no
less consideration. We apologize for any unintentional slight.
Thomas F. Rehring, MD
Ryan S. Stolcpart, PharmD
H. Whitton Hollis Jr, MD
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